Literature DB >> 11401971

Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom.

Q Zhang1, R Lakshman, R Burkinshaw, S Choo, J Everard, S Akhtar, A Finn.   

Abstract

Meningococcal group A+C capsular polysaccharide (PS) conjugate vaccines may prime for serum immunoglobulin G (IgG) memory responses to meningococcal capsular PS. It is not known whether these vaccines induce immunological memory at the mucosal level, which may be important in reducing nasopharyngeal carriage. Mucosal immune responses to meningococcal conjugate and PS vaccines in young adults were investigated. Healthy university students were randomized to receive either a groups A+C meningococcal conjugate vaccine (MACconj, n = 100) or a group A+C meningococcal PS vaccine (MACPS, n = 95). One year after the primary immunization, both groups were randomized again to receive a MACconj or a MACPS booster vaccination. Saliva samples were collected before and 1 month after the primary and booster vaccinations. Anti-meningococcal A (MenA) and C (MenC) PS IgA and IgG antibody levels were measured by a standard enzyme-linked immunosorbent assay. After the primary vaccination, salivary MenA and MenC IgG and MenA IgA concentrations were significantly increased after immunization with both MACconj and MACPS vaccines, but the salivary Men C IgA level was increased only after MACPS vaccine (P < 0.01). IgA responses to both serogroups were greater for MACPS than MACconj vaccine (P < 0.05), whereas no significant differences were seen for IgG responses. MenA IgG titers were higher after the MACPS booster in MACconj-primed subjects than after the MACPS primary vaccination, suggesting the presence of IgG memory. Antibody responses to a dose of either MACPS or MACconj were not significantly reduced in those previously given MACPS compared to the primary responses to those vaccines. Meningococcal A+C conjugate and PS vaccines induce significant mucosal responses in young adults. MACconj priming may induce IgG memory at the mucosal level, which is likely to be a reflection of an anamnestic serum IgG response. No evidence of mucosal hyporesponsiveness was observed after MACPS priming in this study.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11401971      PMCID: PMC98504          DOI: 10.1128/IAI.69.7.4337-4341.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

1.  Salivary antibodies following parenteral immunization of infants with a meningococcal serogroup A and C conjugated vaccine.

Authors:  R Borrow; A J Fox; K Cartwright; N T Begg; D M Jones
Journal:  Epidemiol Infect       Date:  1999-10       Impact factor: 2.451

2.  Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: A randomized controlled trial.

Authors:  J M MacLennan; F Shackley; P T Heath; J J Deeks; C Flamank; M Herbert; H Griffiths; E Hatzmann; C Goilav; E R Moxon
Journal:  JAMA       Date:  2000-06-07       Impact factor: 56.272

3.  Salivary antibody response to vaccination with meningococcal A/C polysaccharide vaccine in previously vaccinated and unvaccinated Gambian children.

Authors:  A Nurkka; J MacLennan; V Jäntti; S Obaro; B Greenwood; H Käyhty
Journal:  Vaccine       Date:  2000-10-15       Impact factor: 3.641

4.  Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory.

Authors:  P Richmond; R Borrow; E Miller; S Clark; F Sadler; A Fox; N Begg; R Morris; K Cartwright
Journal:  J Infect Dis       Date:  1999-06       Impact factor: 5.226

5.  Polysaccharide vaccines of group A Neisseria meningtitidis and Haemophilus influenzae type b: a field trial in Finland.

Authors:  P H Mäkelä; H Peltola; H Käyhty; H Jousimies; O Pettay; E Ruoslahti; A Sivonen; O V Renkonen
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

6.  Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood.

Authors:  J MacLennan; S Obaro; J Deeks; D Williams; L Pais; G Carlone; R Moxon; B Greenwood
Journal:  Vaccine       Date:  1999-08-06       Impact factor: 3.641

7.  Immunologic hyporesponsiveness in man to group C meningococcal polysaccharide.

Authors:  M S Artenstein; B L Brandt
Journal:  J Immunol       Date:  1975-07       Impact factor: 5.422

8.  Vaccination with Haemophilus influenzae type b meningococcal protein conjugate vaccine reduces oropharyngeal carriage of Haemophilus influenzae type b among American Indian children.

Authors:  A K Takala; M Santosham; J Almeido-Hill; M Wolff; W Newcomer; R Reid; H Käyhty; E Esko; P H Mäkelä
Journal:  Pediatr Infect Dis J       Date:  1993-07       Impact factor: 2.129

9.  Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: a clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides.

Authors:  H Peltola; A Safary; H Käyhty; V Karanko; F E André
Journal:  Pediatrics       Date:  1985-07       Impact factor: 7.124

10.  Anti-capsular polysaccharide antibodies reduce nasopharyngeal colonization by Haemophilus influenzae type b in infant rats.

Authors:  M Kauppi; L Saarinen; H Käyhty
Journal:  J Infect Dis       Date:  1993-02       Impact factor: 5.226

View more
  9 in total

Review 1.  Mucosal immunology of vaccines against pathogenic nasopharyngeal bacteria.

Authors:  Q Zhang; A Finn
Journal:  J Clin Pathol       Date:  2004-10       Impact factor: 3.411

2.  Co-colonization by Haemophilus influenzae with Streptococcus pneumoniae enhances pneumococcal-specific antibody response in young children.

Authors:  Qingfu Xu; Michael E Pichichero
Journal:  Vaccine       Date:  2013-12-16       Impact factor: 3.641

Review 3.  Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.

Authors:  Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

4.  Serum antibody kinetics following nasal or parenteral challenge with meningococcal polysaccharide in healthy adults.

Authors:  H Findlow; R Borrow; P Hardelid; E Newton; S Frankland; S Naylor; E Miller; E Kaczmarski; R C Read
Journal:  Clin Vaccine Immunol       Date:  2011-01-19

Review 5.  Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines.

Authors:  David Pace; Andrew J Pollard
Journal:  Arch Dis Child       Date:  2007-10       Impact factor: 3.791

6.  Disparity in functional activity between serum anticapsular antibodies induced in adults by immunization with an investigational group A and C Neisseria meningitidis-diphtheria toxoid conjugate vaccine and by a polysaccharide vaccine.

Authors:  Shannon L Harris; Adam Finn; Dan M Granoff
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

7.  The msbB mutant of Neisseria meningitidis strain NMB has a defect in lipooligosaccharide assembly and transport to the outer membrane.

Authors:  Deborah M B Post; Margaret R Ketterer; Nancy J Phillips; Bradford W Gibson; Michael A Apicella
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

8.  Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine.

Authors:  Mariëtte B van Ravenhorst; Gerco den Hartog; Fiona R M van der Klis; Debbie M van Rooijen; Elisabeth A M Sanders; Guy A M Berbers
Journal:  PLoS One       Date:  2018-04-19       Impact factor: 3.240

9.  Scalable production and immunogenicity of a cholera conjugate vaccine.

Authors:  Suhi Jeon; Meagan Kelly; Jeesun Yun; Byungman Lee; Minchul Park; Yoonhee Whang; Chankyu Lee; Yuan-Di Halvorsen; Smriti Verma; Richelle C Charles; Jason B Harris; Stephen B Calderwood; Daniel T Leung; Taufiqur R Bhuiyan; Firdausi Qadri; Mohammad Kamruzzaman; Somyoung Cho; Willie F Vann; Peng Xu; Pavol Kováč; Ravi Ganapathy; Julia Lynch; Edward T Ryan
Journal:  Vaccine       Date:  2021-10-27       Impact factor: 3.641

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.